The Cholesterol Limbo: How Low Should You Go?

NOTE: This session is part of the Live Intensive Studies and Clinical Sessions packages. All attendees may attend these thought-provoking and highly educational sessions. However, if you are board certified, you must purchase the package(s) for your specialty to receive the recertification assessment and claim the recertification credit.

This session will focus on the hypercholesterolemia treatment recommendations and recent literature supporting the role of statin and nonstatin therapy. Faculty will review clinical trial data, especially with newer agents, as well as discuss role of pharmacists in hypercholesterolemia management. Many clinicians follow the 2018 ACC-AHA cholesterol guideline recommendations as the “gold standard” evidence-based guideline by implementing a fixed-dose, intensity-based statin treatment. This may be appropriate for many patients. However, several high-risk patients may require more intense therapy and targeting further reductions in LDL-C with nonstatin therapy including ezetimibe, PCSK9 inhibitors, bempedoic acid, inclisiran, and icosapent ethyl. This presentation highlights how low cholesterol can go safely to reduce cardiovascular risk, especially in older adults. Interactive case studies will be used to facilitate learning.

This activity is approved for Board Certified Ambulatory Care Pharmacist (BCACP) and Board Certified Geriatric Pharmacist (BCGP) recertification credit.